case_images: PMC10601807_01
case_images: Clinical course of case 1, from the start of VEN+AZA treatment until transplantation. LDH and Plt follow the left axis, and WBC, Hb, and Neu follow the right axis. Myeloblast percentage in BM, WT1 mRNA in PB, and VAF of IDH2R140 mutation in BM are represented by vertical bars. VEN+AZA#1, first cycle of venetoclax and azacitidine combination therapy; VEN+AZA#2, second cycle of venetoclax and azacitidine combination therapy; AZA, azacitidine monotherapy; LDH, lactate dehydrogenase; Plt, platelet count; WBC, white blood cell count; Hb, hemoglobin; Neu, neutrophil count; PB, peripheral blood; BM, bone marrow; Mybl, myeloblast; WT1, Wilms tumor 1; VAF, variant allele frequency.
case_images: cro-2023-0016-0001-533749_F01.jpg
case_images: PMC10601807_01_cro-2023-0016-0001-533749_F01.jpg
case_images: F1
case_images: The clinical course from the start of VEN+AZA treatment to transplantation is shown in Figure 1.
case_images: PMC10601807_02
case_images: Clinical course of case 2, from the start of VEN+AZA treatment until transplantation. LDH and Plt follow the left axis, and WBC, Hb, and Neu follow the right axis. Myeloblast percentage of BM, WT1 mRNA of PB, and VAF of IDH2R172 mutation of BM are represented by vertical bars. VEN+AZA#1, first cycle of venetoclax and azacitidine combination therapy; VEN+AZA#2, second cycle of venetoclax and azacitidine combination therapy; LDH, lactate dehydrogenase; Plt, platelet count; WBC, white blood cell count; Hb, hemoglobin; Neu, neutrophil count; PB, peripheral blood; BM, bone marrow; Mybl, myeloblast; WT1, Wilms tumor 1; VAF, variant allele frequency.
case_images: cro-2023-0016-0001-533749_F02.jpg
case_images: PMC10601807_02_cro-2023-0016-0001-533749_F02.jpg
case_images: F2
case_images: The clinical course from the start of VEN+AZA treatment to transplantation is presented in Figure 2.